Skip to main content

Orchid Cellmark Acquires Strand's Paternity and Immigration Testing Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark said today that it has bought Strand Analytical Laboratories’ paternity and immigration DNA testing business unit for an undisclosed sum.

Indianapolis-based Strand provides forensic, medical, and paternity testing services.

This deal gives Orchid Cellmark Strand’s government paternity, private paternity, and immigration accounts, which last year had revenues of around $450,000.

Orchid Cellmark, headquartered in Princeton, NJ, said that it plans to support these new accounts from its Dayton, Ohio, paternity services facility. Strand will continue to support the clients for its other DNA testing business units.

"While Strand’s paternity business is relatively small in size, the acquisition is consistent with our strategy to grow revenues," Orchid Cellmark CEO and President Thomas Bologna said in a statement.

Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.